000046922 001__ 46922
000046922 005__ 20210121114536.0
000046922 0247_ $$2doi$$a10.3324/haematol.2015.128439
000046922 0248_ $$2sideral$$a92004
000046922 037__ $$aART-2015-92004
000046922 041__ $$aeng
000046922 100__ $$aGarcía-Sanz, R.
000046922 245__ $$aZoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: Results of the randomized AZABACHE Spanish trial
000046922 260__ $$c2015
000046922 5060_ $$aAccess copy available to the general public$$fUnrestricted
000046922 5203_ $$aThis study analyzed the anti-myeloma effect of zoledronic acid monotherapy by investigating patients at the time of asymptomatic biochemical relapse. One hundred patients were randomized to receive either zoledronic acid (4 mg iv/4 weeks, 12 doses) (n=51) or not (n=49). Experimental and control groups were well balanced for disease and prognostic features. Zoledronic acid did not show an antitumor effect according to changes in M-component. However, there were fewer symptomatic progressions in the experimental group than in the control group (34 ver- sus 41, respectively; P=0.05) resulting in a median time to symptoms of 16 versus 10 months (P=0.161). The median time to next therapy was also slightly longer for the treated group than the untreated, control group (13.4 versus 10.1 months), although the difference was not statistically significant (P=0.360). The pattern of relapses was dif- ferent for treated versus control patients: progressive bone disease (8 versus 20), anemia (24 versus 18), renal dysfunc- tion (1 versus 2), and plasmacytomas (1 versus 1, respectively). This concurred with fewer skeletal-related events in the treated group than in the control group (2 versus 14), with a projected 4-year event proportion of 6% versus 40% (P<0.001). In summary, zoledronic acid monotherapy does not show an antitumor effect on biochemical relapses in multiple myeloma, but does reduce the risk of progression with symptomatic bone disease and skeletal compli- cations. This trial was registered in the ClinicalTrials.gov database with code NCT01087008
000046922 536__ $$9info:eu-repo/grantAgreement/ES/MINECO-FEDER/INNOCAMPUS-CEI-2010-1-0010$$9info:eu-repo/grantAgreement/ES/ISCIII/PS09-01450$$9info:eu-repo/grantAgreement/ES/ISCIII/PI12-02311
000046922 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000046922 590__ $$a6.671$$b2015
000046922 591__ $$aHEMATOLOGY$$b4 / 70 = 0.057$$c2015$$dQ1$$eT1
000046922 592__ $$a2.959$$b2015
000046922 593__ $$aHematology$$c2015$$dQ1
000046922 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000046922 700__ $$aOriol, A.
000046922 700__ $$aMoreno, M.J.
000046922 700__ $$aRubia, De La
000046922 700__ $$aPayer, A.R.
000046922 700__ $$aHernández, M.T.
000046922 700__ $$0(orcid)0000-0001-8515-3599$$aPalomera, L.$$uUniversidad de Zaragoza
000046922 700__ $$aTeruel, A.I.
000046922 700__ $$aBlanchard, M.J.
000046922 700__ $$aGironella, M.
000046922 700__ $$aRibas, P.
000046922 700__ $$aBargay, J.
000046922 700__ $$aAbellá, E.
000046922 700__ $$aGranell, M.
000046922 700__ $$aOcio, E.M.
000046922 700__ $$aRibera, J.M.
000046922 700__ $$aSan Miguel, J.F.
000046922 700__ $$aMateos, M.V.
000046922 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000046922 773__ $$g100, 9 (2015), 1207-1213$$pHaematologica$$tHaematologica$$x0390-6078
000046922 8564_ $$s1702986$$uhttps://zaguan.unizar.es/record/46922/files/texto_completo.pdf$$yVersión publicada
000046922 8564_ $$s143444$$uhttps://zaguan.unizar.es/record/46922/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000046922 909CO $$ooai:zaguan.unizar.es:46922$$particulos$$pdriver
000046922 951__ $$a2021-01-21-11:13:24
000046922 980__ $$aARTICLE